MacroGenics (MGNX)
(Delayed Data from NSDQ)
$15.67 USD
+0.45 (2.96%)
Updated May 3, 2024 04:00 PM ET
After-Market: $15.68 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 281 - 300 ( 360 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Rich Pipeline Continues to Advance; Early ''271 Data in H2:15, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
1Q15 Takeaways; Robust Pipeline and Clinical Program Growth
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 4th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Advantage DART''s as Preliminary Solid Tumor CAR-T Underwhelms
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare -Biotechnology: Catalyst Tracker Through Mid-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare: Biotechnology: Its Yogi Berra All Over Again
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
First Peek at Future DART Targets from the AACR-15
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Another Day and Another DART Heads to the Clinic
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MGNX''s Third DART Candidate Advances to Clinic for Treatment of Autoimmune Disorders
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: MacroGenics, Inc.
Industry: Medical - Products
Q4:14 EPS; on Track for Multiple Trial Initiations for 2015; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Well Positioned and Expanding Pipeline Supported by Cash till 2018
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D